Search for: "A & R Productions" Results 1901 - 1920 of 99,370
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
29 Mar 2022, 9:05 am by Kyle Hulehan
Brian Kemp (R) recently signed legislation providing $1.1 billion worth of tax rebates, in the form of $250 to $500 per household checks (capped at actual tax liability). [read post]
28 Mar 2022, 6:32 am by Kyle Hulehan
Many measures focus on tax relief for Research and Development (R&D), such as the simultaneous application of the R&D and patent box’s tax relief or a 200 percent deduction for certain R&D expenditures. [read post]
27 Mar 2022, 9:08 pm by Nives Dolšak
The older CSR movement originated in the 1950s with Howard R. [read post]
25 Mar 2022, 12:44 am by Mridu Katoch
Yes, especially if you are bringing your product to market. [read post]
24 Mar 2022, 1:36 pm by Rebecca Tushnet
” “[R]umors began to emerge that Abbott was preparing to launch a B. infantis product that would compete with EVIVO,” allegedly causing Evolve to lose business. [read post]
24 Mar 2022, 12:22 pm by Brad Schnure
(SenateNJ.com) The resolution, SR-74, urges the United States Congress and the President to increase domestic energy production and to lessen regulatory burdens that prevent that from happening. [read post]
24 Mar 2022, 9:47 am by Kyle Hulehan
Jackie Walorski (R-IN) and Jim Banks (R-IN) introduced a commonsense policy to boost U.S. competitiveness. [read post]
24 Mar 2022, 6:02 am by Searcy Law
While it isn’t yet clear what happened with regard to Avandia, it is not unusual for drug companies to attempt to conceal information about risks associated with their products. [read post]
24 Mar 2022, 6:02 am by Searcy Law
While it isn’t yet clear what happened with regard to Avandia, it is not unusual for drug companies to attempt to conceal information about risks associated with their products. [read post]
24 Mar 2022, 6:02 am by Searcy Law
While it isn’t yet clear what happened with regard to Avandia, it is not unusual for drug companies to attempt to conceal information about risks associated with their products. [read post]
19 Mar 2022, 2:09 pm by admin
The agency assessing risk may decide to bar a substance or product if the potential benefits are outweighed by the possibility of risks that are largely unquantifiable because of presently unknown contingencies. [read post]